Scholarlink

Background <p>This study aimed to evaluate the effectiveness of a novel nostril protection device for reducing the incidence, severity, and pain associated with medical device-related pressure ulcers (MDRPUs) in patients undergoing endoscopic transnasal skull base surgery (ETSBS).</p> Methods <p>This within-person, quasi-randomized, patient-blinded, single-center trial included 18 patients who underwent ETSBS. The Nostril Protector (Daiichi Medical, Tokyo, Japan) was applied to one nostril (treatment side), while the contralateral nostril served as the control. The incidence and severity of MDRPUs were assessed using the National Pressure Ulcer Advisory Panel (NPUAP) classification. Pain was evaluated using a numerical rating scale (NRS) at 0, 2, and 4&#xa0;days postoperatively.</p> Results <p>The incidence of MDRPUs was significantly lower on the treated side than on the control side on postoperative days 2 and 4. Notably, no patients developed grade 2 or higher MDRPUs on the treatment side. While pain scores tended to be lower on the treated side, the difference was not statistically significant.</p> Conclusions <p>The use of the Nostril Protector effectively reduced the incidence and severity of MDRPUs during ETSBS. Although the reduction in pain was not significant, the device demonstrates clear potential as a preventive measure against MDRPUs in prolonged endoscopic procedures.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of nostril protector in preventing device-related pressure ulcers during endoscopic transnasal skull base surgery: a within-person quasi-randomized trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月1日

查看全文
  • Naoya Nishida,
  • Kunihide Aoishi,
  • Taishin Motooka,
  • Akihiro Inoue,
  • Satoshi Suehiro,
  • Naohito Hato

摘要

Background

This study aimed to evaluate the effectiveness of a novel nostril protection device for reducing the incidence, severity, and pain associated with medical device-related pressure ulcers (MDRPUs) in patients undergoing endoscopic transnasal skull base surgery (ETSBS).

Methods

This within-person, quasi-randomized, patient-blinded, single-center trial included 18 patients who underwent ETSBS. The Nostril Protector (Daiichi Medical, Tokyo, Japan) was applied to one nostril (treatment side), while the contralateral nostril served as the control. The incidence and severity of MDRPUs were assessed using the National Pressure Ulcer Advisory Panel (NPUAP) classification. Pain was evaluated using a numerical rating scale (NRS) at 0, 2, and 4 days postoperatively.

Results

The incidence of MDRPUs was significantly lower on the treated side than on the control side on postoperative days 2 and 4. Notably, no patients developed grade 2 or higher MDRPUs on the treatment side. While pain scores tended to be lower on the treated side, the difference was not statistically significant.

Conclusions

The use of the Nostril Protector effectively reduced the incidence and severity of MDRPUs during ETSBS. Although the reduction in pain was not significant, the device demonstrates clear potential as a preventive measure against MDRPUs in prolonged endoscopic procedures.